Literature DB >> 23042884

Synaptic dysfunction in depression: potential therapeutic targets.

Ronald S Duman1, George K Aghajanian.   

Abstract

Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to months. A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants. Basic studies show that ketamine rapidly induces synaptogenesis and reverses the synaptic deficits caused by chronic stress. These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23042884      PMCID: PMC4424898          DOI: 10.1126/science.1222939

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  49 in total

Review 1.  Long-term depression in the CNS.

Authors:  Graham L Collingridge; Stephane Peineau; John G Howland; Yu Tian Wang
Journal:  Nat Rev Neurosci       Date:  2010-07       Impact factor: 34.870

2.  Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex.

Authors:  E Ampuero; F J Rubio; R Falcon; M Sandoval; G Diaz-Veliz; R E Gonzalez; N Earle; A Dagnino-Subiabre; F Aboitiz; F Orrego; U Wyneken
Journal:  Neuroscience       Date:  2010-04-22       Impact factor: 3.590

3.  Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression.

Authors:  Anteneh M Feyissa; Agata Chandran; Craig A Stockmeier; Beata Karolewicz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-10-25       Impact factor: 5.067

Review 4.  mTOR signaling: at the crossroads of plasticity, memory and disease.

Authors:  Charles A Hoeffer; Eric Klann
Journal:  Trends Neurosci       Date:  2009-12-04       Impact factor: 13.837

5.  Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial.

Authors:  Wayne C Drevets; Maura L Furey
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

Review 6.  Neurocircuitry of mood disorders.

Authors:  Joseph L Price; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

7.  Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation.

Authors:  Hussam Jourdi; Yu-Tien Hsu; Miou Zhou; Qingyu Qin; Xiaoning Bi; Michel Baudry
Journal:  J Neurosci       Date:  2009-07-08       Impact factor: 6.167

8.  Dendritic trafficking of BDNF mRNA is mediated by translin and blocked by the G196A (Val66Met) mutation.

Authors:  C Chiaruttini; A Vicario; Z Li; G Baj; P Braiuca; Y Wu; F S Lee; L Gardossi; J M Baraban; E Tongiorgi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-09       Impact factor: 11.205

9.  Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety.

Authors:  J M Gatt; C B Nemeroff; C Dobson-Stone; R H Paul; R A Bryant; P R Schofield; E Gordon; A H Kemp; L M Williams
Journal:  Mol Psychiatry       Date:  2009-01-20       Impact factor: 15.992

10.  Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis.

Authors:  D Taliaz; N Stall; D E Dar; A Zangen
Journal:  Mol Psychiatry       Date:  2009-07-21       Impact factor: 15.992

View more
  443 in total

Review 1.  The Netrin-1/DCC Guidance Cue Pathway as a Molecular Target in Depression: Translational Evidence.

Authors:  Angélica Torres-Berrío; Giovanni Hernandez; Eric J Nestler; Cecilia Flores
Journal:  Biol Psychiatry       Date:  2020-05-11       Impact factor: 13.382

Review 2.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

3.  The effects of lobeline on nicotine withdrawal-induced depression-like behavior in mice.

Authors:  Monzurul Amin Roni; Shafiqur Rahman
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

4.  The antidepressant-like effect of guanosine is dependent on GSK-3β inhibition and activation of MAPK/ERK and Nrf2/heme oxygenase-1 signaling pathways.

Authors:  Priscila B Rosa; Luis E B Bettio; Vivian B Neis; Morgana Moretti; Isabel Werle; Rodrigo B Leal; Ana Lúcia S Rodrigues
Journal:  Purinergic Signal       Date:  2019-11-25       Impact factor: 3.765

Review 5.  Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

Authors:  Chadi G Abdallah; Lynnette A Averill; John H Krystal
Journal:  Ann N Y Acad Sci       Date:  2015-02-27       Impact factor: 5.691

6.  Regulation of brain-derived neurotrophic factor expression in neurons.

Authors:  Fei Zheng; Xianju Zhou; Changjong Moon; Hongbing Wang
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-12-26

7.  Novel antidepressant effects of Paeonol alleviate neuronal injury with concomitant alterations in BDNF, Rac1 and RhoA levels in chronic unpredictable mild stress rats.

Authors:  Xiu-Ling Zhu; Jing-Jing Chen; Fei Han; Chuan Pan; Ting-Ting Zhuang; Ya-Fei Cai; Ya-Ping Lu
Journal:  Psychopharmacology (Berl)       Date:  2018-05-12       Impact factor: 4.530

Review 8.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

9.  Modulation of motor cortex excitability predicts antidepressant response to prefrontal cortex repetitive transcranial magnetic stimulation.

Authors:  Albino J Oliveira-Maia; Daniel Press; Alvaro Pascual-Leone
Journal:  Brain Stimul       Date:  2017-03-31       Impact factor: 8.955

Review 10.  The organization of the stress system and its dysregulation in depressive illness.

Authors:  P W Gold
Journal:  Mol Psychiatry       Date:  2014-12-09       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.